Oncotarget

Reviews:

Next generation sequencing and its applications in HPV-associated cancers

Musaffe Tuna _ and Christopher I. Amos

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:8877-8889. https://doi.org/10.18632/oncotarget.12830

Metrics: PDF 2722 views  |   HTML 4159 views  |   ?  


Abstract

Musaffe Tuna1 and Christopher I. Amos1

1 Department of Biomedical Data Science, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA

Correspondence to:

Musaffe Tuna, email:

Keywords: next-generation sequencing, genomics, omics, mutations, HPV-driven cancers

Received: May 30, 2016 Accepted: October 14, 2016 Published: October 23, 2016

Abstract

Approximately 18% of all human cancers have a viral etiology, and human papillomavirus (HPV) has been identified as one of the most prevalent viruses that plays causative role in nearly all cervical cancers and, in addition, in subset of head and neck, anal, penile and vulvar cancers. The recent introduction of next generation sequencing (NGS) and other ‘omics’ approaches have resulted in comprehensive knowledge on the pathogenesis of HPV-driven tumors. Specifically, these approaches have provided detailed information on genomic HPV integration sites, disrupted genes and pathways, and common and distinct genetic and epigenetic alterations in different human HPV-associated cancers. This review focuses on HPV integration sites, its concomitantly disrupted genes and pathways and its functional consequences in both cervical and head and neck cancers. Integration of NGS data with other ‘omics’ and clinical data is crucial to better understand the pathophysiology of each individual malignancy and, based on this, to select targets and to design effective personalized treatment options.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12830